Skip to main content
Ipsen logo

Ipsen — Investor Relations & Filings

Ticker · IPN ISIN · FR0010259150 LEI · 549300M6SGDPB4Z94P11 PA Manufacturing
Open in API
Filings indexed 1,378 across all filing types
Latest filing 2022-03-09 Declaration of Voting R…
Country FR France
Listing PA IPN

About Ipsen

https://www.ipsen.com/

Ipsen is a global biopharmaceutical company focused on innovation and specialty care. The company develops and commercializes transformative medicines to address high unmet medical needs in three key therapeutic areas: oncology, rare diseases, and neuroscience. By leveraging its specialized expertise and strategic partnerships, Ipsen aims to accelerate the development of new therapies and improve health outcomes for patients worldwide. Its strategy is centered on advancing science with purpose to bring innovative treatments from research and development to the market.

Recent filings

Filing Released Lang Actions
Total number of voting rights and capital / Information on the total number of voting rights and the number of shares making up the capital
Declaration of Voting Results & Voting Rights Announcements Classification · 1% confidence The document is titled "Monthly information relative to the total number of voting rights and shares composing the share capital" and provides a table detailing the total number of shares and voting rights as of February 28, 2022. It explicitly references French regulatory articles (L.233-8 II of the French Commercial Code and Article 223-16 of the AMF General Regulation). This type of regular disclosure concerning the total share capital and voting rights structure is a standard regulatory filing, often required monthly or quarterly. It does not fit the specific definitions for Annual Reports (10-K), Earnings Releases (ER), or Dividend Notices (DIV). Since it is a specific, recurring regulatory disclosure that doesn't map perfectly to the other specialized codes (like DIRS, MRQ, or DVA which deal with specific transactions or results), the most appropriate general regulatory category is 'Regulatory Filings' (RNS), although it is highly specific. Given the options, RNS serves as the best fit for mandatory, recurring regulatory disclosures not covered elsewhere. It is not an announcement of a report (RPA) but the report itself.
2022-03-09 English
Informations privilégiées / Autres communiqués
Environmental & Social Information Classification · 1% confidence The document is a press release from Ipsen, dated March 8, 2022, announcing new data from patient surveys (PRESTO 2 and HomeLAN) that will be presented at the 19th annual European Neuroendocrine Tumor Society (ENETS) conference. It details clinical findings related to the drug Somatuline® Autogel®/Somatuline® Depot (lanreotide), including patient satisfaction and injection site pain comparisons. This content is characteristic of an announcement summarizing clinical trial or survey results, often released ahead of or concurrent with a major medical conference. It is not a full Annual Report (10-K), a formal Audit Report (AR), a comprehensive Interim Report (IR), or a standard Earnings Release (ER). Since it is a formal announcement of clinical data and research findings, it fits best under the general category of Investor Information or a specific regulatory/scientific disclosure. Given the options, this is a scientific/clinical data announcement, which often falls under general Regulatory Filings (RNS) if no other specific category applies, or sometimes an Investor Presentation (IP) if it were structured as slides, but here it functions as a news release detailing study outcomes. Since it is a press release announcing data presented at a conference, and not a formal financial filing like 10-K or a specific report type like AR or IR, the most appropriate general category for a corporate announcement of scientific data is RNS (Regulatory Filings/General Announcement). However, given the focus on presenting data to investors/the public about a drug's performance, it is a form of Investor Information. Since 'Investor Presentation' (IP) is for slides, and 'Earnings Release' (ER) is for financial results, 'RNS' serves as the best fit for a scientific press release announcement.
2022-03-08 French
Inside Information / Other news releases
Earnings Release Classification · 1% confidence The document is a press release from Ipsen announcing new patient-reported data from seven abstracts to be presented at the 19th Annual European Neuroendocrine Tumor Society (ENETS) Conference. It details findings from the PRESTO 2 and HomeLAN surveys regarding patient satisfaction and injection-site pain related to their drug, Somatuline® Autogel®. This content is typical of a company communicating scientific or clinical updates, often preceding or accompanying a major medical conference. It is not a formal regulatory filing like a 10-K, a comprehensive quarterly report (IR), or a simple earnings release (ER). It is a detailed communication aimed at investors and the medical community about clinical data. This fits best under Investor Presentation (IP) as it presents detailed data and analysis, although it is formatted as a press release. Given the context of presenting detailed study results (PRESTO 2, HomeLAN) and listing all abstracts to be presented at a conference, 'Investor Presentation' (IP) is the most appropriate category for this type of detailed scientific/clinical data dissemination. FY 2020
2022-03-08 English
Informations privilégiées / Autres communiqués
Board/Management Information Classification · 1% confidence The document is a press release announcing the appointment of a new Executive Vice President, Catherine Abi-Habib, to the Strategy, Transformation, and Digital role, effective March 1, 2022. It details her background, quotes the CEO, and provides standard company boilerplate information and forward-looking statements. This type of announcement, concerning changes in senior leadership (Board or Management), directly corresponds to the definition for Board/Management Information (MANG). It is not an earnings release (ER), a full annual report (10-K), or a transcript (CT).
2022-02-16 French
Inside Information / Other news releases
Board/Management Information Classification · 1% confidence The document is an official announcement dated February 16, 2022, detailing the appointment of a new Executive Vice President (Catherine Abi-Habib) to the senior management team, effective March 1st, 2022. This content directly relates to changes in the company's senior management structure. According to the definitions, this aligns perfectly with the 'Board/Management Information' category (Code: MANG). It is not an earnings release, a full annual report, or a proxy statement.
2022-02-16 English
Inside Information / Other news releases
Investor Presentation Classification · 1% confidence The document is a press release from Ipsen announcing updated results from the Phase III CheckMate -9ER clinical trial regarding the combination therapy Cabometyx® and Opdivo® for advanced renal cell carcinoma. It details efficacy endpoints (OS, PFS, ORR), safety profiles, and quality of life improvements, referencing presentations at the ASCO GU 2022 symposium. This content is characteristic of an announcement summarizing clinical trial data and its implications, often released ahead of or concurrent with a major medical conference presentation. It is not a formal regulatory filing like a 10-K, a standalone Audit Report (AR), a formal Earnings Release (ER) focusing on quarterly financials, or a Call Transcript (CT). Since it is a detailed announcement of clinical data and scientific findings, it best fits the category of Investor Presentation (IP) or potentially a Regulatory Filing (RNS) if no better fit exists. Given the detailed scientific and clinical data presentation aimed at investors and the medical community, 'Investor Presentation' (IP) is the most appropriate classification, even though it is presented as a press release, as it functions as a detailed informational package for stakeholders regarding product performance. However, reviewing the definitions again, 'Investor Presentation' (IP) usually refers to slide decks. This is a press release detailing clinical trial updates. Since it is not a formal financial report (10-K, IR, ER) but rather a detailed update on a drug's performance, and it is not a short announcement of a report (RPA), it falls into the category of providing specific, non-financial operational/scientific information to investors. In the absence of a specific 'Clinical Trial Update' category, 'Investor Presentation' (IP) captures the intent of disseminating detailed performance data to the investment community. If the document were shorter and just announced the availability of these results, it would be RPA/RNS. Since it contains the substance of the findings, IP is chosen over the general 'RNS'.
2022-02-15 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.